The incidence of MGUS was 17% among Black patients.
Researchers observed a similar incidence of SARS-CoV-2 infections in vaccinated and unvaccinated patients with multiple myeloma.
CT103A yielded responses in patients who had received prior murine BCMA CAR T-cell therapy.
Overall survival was longest with first-line daratumumab plus lenalidomide and dexamethasone.
The stringent complete response rate increased from 67% at 1 year to 83% at 2 years.
More than one-third of patients had intermediate- or high-risk smoldering multiple myeloma.